LGVN - Biotech - Pre data realese pump expected - fast play!

2024년 10월 27일

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

1. Float 12.465M
   
2. Phase 2a - Data Releas on 21/10/2024
   

Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.

Resistance Points:

$2.80
$3.49

Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.

Trading Strategy:

I expect a quick pre-pump before the news. Afterwards, it could crash hard, so stay ready and be careful.

Take Profit (TP): Set a target at $4.00 (pre catalyst run up)

Stop Loss (SL): Set at under $1.9 to mitigate potential losses.

Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.

Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.

Disclaimer: This content is for informational purposes only and should not be considered financial advice.

2024년 10월 27일

노트

I mean catalyst on 29/10/2024